Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Lynn SeelyPresident and CEO | Lyell ImmunopharmaLYEL | Open-market sale | 05/11 | 06/15 | 388 sh | $18.91 | $7,337.08 | −0.5% |
Lyell ImmunopharmaLYEL | Open-market sale | 05/11 | 06/15 | 89 sh | $18.92 | $1,683.88 | −0.5% | |
Gary K. LeeChief Scientific Officer | Lyell ImmunopharmaLYEL | Open-market sale | 05/11 | 06/15 | 130 sh | $18.92 | $2,459.6 | −0.7% |
Veronica Sanchez BulisVP, Corporate Controller | Lyell ImmunopharmaLYEL | Open-market sale | 05/11 | 06/15 | 217 sh | $18.91 | $4,103.47 | −1.4% |
David ShookChief Medical Officer | Lyell ImmunopharmaLYEL | Open-market sale | 06/10 | 06/11 | 1,977 sh | $12.64 | $24,989.28 | −8.6% |
Berns Paul L.10% Owner | Lyell ImmunopharmaLYEL | Open-market buy | 03/06 | 03/09 | 488,090 sh | $25.61 | $12,499,984.9 | +52.0% |
Keith Crandell10% Owner | Lyell ImmunopharmaLYEL | Open-market buy | 03/06 | 03/09 | 488,090 sh | $25.61 | $12,499,984.9 | +52.0% |
Robert Nelsen10% Owner | Lyell ImmunopharmaLYEL | Open-market buy | 03/06 | 03/09 | 488,090 sh | $25.61 | $12,499,984.9 | +52.0% |
Clinton Bybee10% Owner | Lyell ImmunopharmaLYEL | Open-market buy | 03/06 | 03/09 | 488,090 sh | $25.61 | $12,499,984.9 | +52.0% |
Steven Gillis10% Owner | Lyell ImmunopharmaLYEL | Open-market buy | 03/06 | 03/09 | 488,090 sh | $25.61 | $12,499,984.9 | +52.0% |
Kristina Burow10% Owner | Lyell ImmunopharmaLYEL | Open-market buy | 03/06 | 03/09 | 488,090 sh | $25.61 | $12,499,984.9 | +52.0% |
Arch Venture Fund IX10% Owner | Lyell ImmunopharmaLYEL | Open-market buy | 03/06 | 03/09 | 488,090 sh | $25.61 | $12,499,984.9 | +52.0% |
Arch Venture Fund IX Overage10% Owner | Lyell ImmunopharmaLYEL | Open-market buy | 03/06 | 03/09 | 488,090 sh | $25.61 | $12,499,984.9 | +52.0% |
Arch Venture Partners IX Overage10% Owner | Lyell ImmunopharmaLYEL | Open-market buy | 03/06 | 03/09 | 488,090 sh | $25.61 | $12,499,984.9 | +52.0% |
Arch Venture Partners IX10% Owner | Lyell ImmunopharmaLYEL | Open-market buy | 03/06 | 03/09 | 488,090 sh | $25.61 | $12,499,984.9 | +52.0% |
Arch Venture Partners IX10% Owner | Lyell ImmunopharmaLYEL | Open-market buy | 03/06 | 03/09 | 488,090 sh | $25.61 | $12,499,984.9 | +52.0% |
Arch Venture Fund Xiii10% Owner | Lyell ImmunopharmaLYEL | Open-market buy | 03/06 | 03/09 | 488,090 sh | $25.61 | $12,499,984.9 | +52.0% |
Arch Venture Partners Xiii10% Owner | Lyell ImmunopharmaLYEL | Open-market buy | 03/06 | 03/09 | 488,090 sh | $25.61 | $12,499,984.9 | +52.0% |
Arch Venture Partners Xiii10% Owner | Lyell ImmunopharmaLYEL | Open-market buy | 03/06 | 03/09 | 488,090 sh | $25.61 | $12,499,984.9 | +52.0% |
Lynn SeelyPresident and CEO | Lyell ImmunopharmaLYEL | Open-market sale | 02/11 | 02/12 | 7,455 sh | $23.39 | $174,372.45 | −9.1% |